Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZIKV E + 102CpG
- Development stage
- Preclinical
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
ZIKV E + 102CpG is an experimental Zika virus vaccine candidate that combines recombinant Zika virus envelope protein (E protein, ZIKV E) with the immunostimulatory CpG oligonucleotide "102CpG"[5][6]. The ZIKV E protein, the main surface glycoprotein of Zika virus, is responsible for host-cell entry and is a major target for neutralizing antibody responses[5][11]. CpG oligonucleotides act as adjuvants that activate the innate immune system via Toll-like receptor 9 (TLR9), enhancing the adaptive immune response to the E protein[6]. This combination aims to generate strong and specific Zika-neutralizing antibodies and robust cellular immunity. As of October 2025, ZIKV E + 102CpG is an investigational subunit vaccine in preclinical research, primarily indicated for prophylactic immunization against Zika virus infection.
- Brand names
- ZIKV E + 102CpG
- Other names
- ZIKV E + 102CpG
02
Targets
Gag (HIV-1 Gag polyprotein)TLR9 (Toll-like receptor 9)ZIKV E (Zika virus envelope protein)
Beyond the preview
Go deeper on ZIKV E + 102CpG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZIKV E + 102CpG.